Dr. Jakubowiak Discusses the Toxicity Profile of Panobinostat in the PANORAMA Trial

Andrzej Jakubowiak, MD, PhD
Published Online: Tuesday, June 17, 2014
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.

Jakubowiak says ideally, researchers aim to create a drug or drug combination that is more active with less toxicity. In the PANORAMA trial, there was a higher proportion of GI toxicities in the panobinistat arm compared to the placebo arm. There was also a higher rate of thrombocytopenia and other hematological toxicities. However, all of the toxicities were mostly manageable and did not impact the outcome, Jakubowiak says.

More details are needed to get a better understanding of the toxicity profile of this combination in this setting, Jakubowiak says.

Online CME Activities
Free CME from PER
Community Practice Connections™: 16th Annual International Lung Cancer Congress®
Community Practice Connections™: 14th Annual International Congress on the Future of Breast Cancer®
Oncology Consultations®: Integrating Molecular Testing into the Breast Cancer Treatment Paradigm
Role of the Nurse in Facilitating Adherence to Oral Therapies in Oncology Practice
More Reading